請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24267
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄧哲明 | |
dc.contributor.author | Szu-Ying Wu | en |
dc.contributor.author | 吳思穎 | zh_TW |
dc.date.accessioned | 2021-06-08T05:20:12Z | - |
dc.date.copyright | 2005-08-12 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-28 | |
dc.identifier.citation | 1. Acehan,D., Jiang,X., Morgan,D.G., Heuser,J.E., Wang,X., and Akey,C.W. (2002) Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol.Cell, 9, 423-432.
2. Adams,J.M. and Cory,S. (2002) Apoptosomes: engines for caspase activation. Curr.Opin.Cell Biol., 14, 715-720. 3. Ashkenazi,A. and Dixit,V.M. (1998) Death receptors: signaling and modulation. Science, 281, 1305-1308. 4. Ashkenazi,A. and Dixit,V.M. (1999) Apoptosis control by death and decoy receptors. Curr.Opin.Cell Biol., 11, 255-260. 5. Basanez,G., Sharpe,J.C., Galanis,J., Brandt,T.B., Hardwick,J.M., and Zimmerberg,J. (2002) Bax-type Apoptotic Proteins Porate Pure Lipid Bilayers through a Mechanism Sensitive to Intrinsic Monolayer Curvature. Journal of Biological Chemistry, 277, 49360-49365. 6. Birner,P., Schindl,M., Obermair,A., Plank,C., Breitenecker,G., and Oberhuber,G. (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res., 60, 4693-4696. 7. Blaschke,S., Mueller,C.A., Markovic-Lipkovski,J., Puch,S., Miosge,N., Becker,V., Mueller,G.A., and Klein,G. (2002) Expression of cadherin-8 in renal cell carcinoma and fetal kidney. Int.J Cancer, 101, 327-334. 8. Bossy-Wetzel,E. and Green,D.R. (1999) Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. J.Biol.Chem., 274, 17484-17490. 9. Cande,C., Vahsen,N., Garrido,C., and Kroemer,G. (2004) Apoptosis-inducing factor (AIF): caspase-independent after all. Cell Death.Differ., 11, 591-595. 10. Chai,J., Du,C., Wu,J.W., Kyin,S., Wang,X., and Shi,Y. (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature, 406, 855-862. 11. Chang,L. and Karin,M. (2001) Mammalian MAP kinase signalling cascades. Nature, 410, 37-40. 12. Chang,M.S., Lee,W.S., Teng,C.M., Lee,H.M., Sheu,J.R., Hsiao,G., and Lin,C.H. (2002) YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells. Br.J Pharmacol, 136, 558-567. 13. Chun,Y.S., Kim,M.S., and Park,J.W. (2002) Oxygen-dependent and -independent regulation of HIF-1alpha. J Korean Med.Sci., 17, 581-588. 14. Chun,Y.S., Yeo,E.J., Choi,E., Teng,C.M., Bae,J.M., Kim,M.S., and Park,J.W. (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem.Pharmacol, 61, 947-954. 15. Chun,Y.S., Yeo,E.J., and Park,J.W. (2004) Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett., 207, 1-7. 16. Cohen,G.M. (1997) Caspases: the executioners of apoptosis. Biochem.J, 326 ( Pt 1), 1-16. 17. Czyzyk-Krzeska,M.F. (1997) Molecular aspects of oxygen sensing in physiological adaptation to hypoxia. Respir.Physiol, 110, 99-111. 18. Davis,R.J. (2000) Signal transduction by the JNK group of MAP kinases. Cell, 103, 239-252. 19. Desagher,S. and Martinou,J.C. (2000) Mitochondria as the central control point of apoptosis. Trends in Cell Biology, 10, 369-377. 20. Earnshaw,W.C., Martins,L.M., and Kaufmann,S.H. (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu.Rev.Biochem., 68, 383-424. 21. Eskes,R., Desagher,S., Antonsson,B., and Martinou,J.C. (2000) Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Molecular and Cellular Biology, 20, 929-935. 22. Esposti,M.D. (2002) The roles of Bid. Apoptosis, 7, 433-440. 23. Friebe,A. and Koesling,D. (1998) Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol.Pharmacol, 53, 123-127. 24. Gajate C,F.R.C.C.A.-N.G.A.-R.Y.M.M.M.F. (2000) Intracellular Triggering of Fas, Independently of FasL, as a New Mechanism of Antitumor Ether Lipid-induced Apoptosis. Int.J.Cancer: 85, 674-682. 25. Gajate,C., Del Canto-Janez,E., Acuna,A.U., mat-Guerri,F., Geijo,E., Santos-Beneit,A.M., Veldman,R.J., and Mollinedo,F. (2004) Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med., 200, 353-365. 26. Galle,J., Zabel,U., Hubner,U., Hatzelmann,A., Wagner,B., Wanner,C., and Schmidt,H.H. (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br.J Pharmacol, 127, 195-203. 27. Giaccia,A., Siim,B.G., and Johnson,R.S. (2003) HIF-1 as a target for drug development. Nat.Rev.Drug Discov., 2, 803-811. 28. Griffith,T.S. and Lynch,D.H. (1998) TRAIL: a molecule with multiple receptors and control mechanisms. Curr.Opin.Immunol., 10, 559-563. 28. Heiser,D., Labi,V., Erlacher,M., and Villunger,A. (2004) The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol., 39, 1125-1135. 30. Hengartner,M.O. (2000) The biochemistry of apoptosis. Nature, 407, 770-776. 31. Hibi,M., Lin,A., Smeal,T., Minden,A., and Karin,M. (1993) Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes and Development, 7, 2135-2148. 32. Hoenicka,M., Becker,E.M., Apeler,H., Sirichoke,T., Schroder,H., Gerzer,R., and Stasch,J.P. (1999) Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol.Med., 77, 14-23. 33. Hong,S.J., Dawson,T.M., and Dawson,V.L. (2004) Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci., 25, 259-264. 34. Hsieh,G.C., O'Neill,A.B., Moreland,R.B., Sullivan,J.P., and Brioni,J.D. (2003) YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur.J Pharmacol, 458, 183-189. 35. Huang,Y.T., Pan,S.L., Guh,J.H., Chang,Y.L., Lee,F.Y., Kuo,S.C., and Teng,C.M. (2005) YC-1 suppresses constitutive nuclear factor-kB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther., revised. 36. Jeremias,I., Herr,I., Boehler,T., and Debatin,K.M. (1998) TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur.J Immunol., 28, 143-152. 37. Johnstone,R.W., Ruefli,A.A., and Lowe,S.W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108, 153-164. 38. Kass,G.E., Eriksson,J.E., Weis,M., Orrenius,S., and Chow,S.C. (1996) Chromatin condensation during apoptosis requires ATP. Biochem.J., 318 ( Pt 3), 749-752. 39. Kaufmann,S.H. and Hengartner,M.O. (2001) Programmed cell death: alive and well in the new millennium. Trends in Cell Biology, 11, 526-534. 40. Kaufmann,T., Schlipf,S., Sanz,J., Neubert,K., Stein,R., and Borner,C. (2003) Characterization of the signal that directs Bcl-xL, but not Bcl-2, to the mitochondrial outer membrane. The Journal of Cell Biology, 160, 53-64. 41. Kerr,J.F., Wyllie,A.H., and Currie,A.R. (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br.J.Cancer, 26, 239-257. 42. Ko,F.N., Wu,C.C., Kuo,S.C., Lee,F.Y., and Teng,C.M. (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood, 84, 4226-4233. 43. Kurosu,K., Saeki,M., and Kamisaki,Y. (2004) Formation of high molecular weight caspase-3 complex in neonatal rat brain. Neurochem.Int., 44, 199-204. 44. Lee,Y.C., Martin,E., and Murad,F. (2000) Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc.Natl.Acad.Sci.U.S.A, 97, 10763-10768. 45. Levee,M.G., Dabrowska,M.I., Lelli,J.L., Jr., and Hinshaw,D.B. (1996) Actin polymerization and depolymerization during apoptosis in HL-60 cells. Am.J Physiol, 271, C1981-C1992. 46. Lin,A. (2003) Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays, 25, 17-24. 47. Marsters,S.A., Pitti,R.M., Donahue,C.J., Ruppert,S., Bauer,K.D., and Ashkenazi,A. (1996) Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr.Biol., 6, 750-752. 48. Martel,C.L. and Lara,P.N. (2003) Renal cell carcinoma: current status and future directions. Crit Rev.Oncol.Hematol., 45, 177-190. 49. McLaughlin,J.K. and Lipworth,L. (2000) Epidemiologic aspects of renal cell cancer. Semin.Oncol., 27, 115-123. 50. Meloni-Ehrig,A.M. (2002) Renal cancer: cytogenetic and molecular genetic aspects. Am.J Med.Genet., 115, 164-172. 51. Olson,J.M. and Hallahan,A.R. (2004) p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med., 10, 125-129. 52. Pan,G., O'Rourke,K., and Dixit,V.M. (1998) Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J.Biol.Chem., 273, 5841-5845. 53. Pan,S.L., Guh,J.H., Peng,C.Y., Chang,Y.L., Cheng,F.C., Chang,J.H., Kuo,S.C., Lee,F.Y., and Teng,C.M. (2005) A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb.Haemost., 93, 940-948. 54. Pan,S.L., Guh,J.H., Peng,C.Y., Wang,S.W., Chang,Y.L., Cheng,F.C., Chang,J.H., Kuo,S.C., Lee,F.Y., and Teng,C.M. (2005) YC-1 [3-(5'-Hydroxymethyl-2'-Furyl)-1-Benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors In Vitro and Angiogenesis In Vivo Models. Journal of Pharmacology And Experimental Therapeutics. 55. Pirollo,K.F., Bouker,K.B., and Chang,E.H. (2000) Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs, 11, 419-432. 56. Russwurm,M., Mergia,E., Mullershausen,F., and Koesling,D. (2002) Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol.Chem., 277, 24883-24888. 57. Ryan,H.E., Poloni,M., McNulty,W., Elson,D., Gassmann,M., Arbeit,J.M., and Johnson,R.S. (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res., 60, 4010-4015. 58. Sakahira,H., Enari,M., and Nagata,S. (1998) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature, 391, 96-99. 59. Sakahira,H., Enari,M., and Nagata,S. (1999) Functional differences of two forms of the inhibitor of caspase-activated DNase, ICAD-L, and ICAD-S. J.Biol.Chem., 274, 15740-15744. 60. Samejima,K. and Earnshaw,W.C. (1998) ICAD/DFF regulator of apoptotic nuclease is nuclear. Exp.Cell Res., 243, 453-459. 61. Schultz,D. and Harringto,W. (2003) Apoptosis: Programmed cell death at a molecular level. Seminars in Arthritis and Rheumatism, 32, 345-369. 62. Semenza,G.L. (2003) Targeting HIF-1 for cancer therapy. Nat.Rev.Cancer, 3, 721-732. 63. Semenza,G.L. (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr.Opin.Genet.Dev., 8, 588-594. 64. Semenza,G.L. (2003) Targeting HIF-1 for cancer therapy. Nat.Rev.Cancer, 3, 721-732. 65. Shaulian,E. and Karin,M. (2002) AP-1 as a regulator of cell life and death. Nat.Cell Biol., 4, E131-E136. 66. Sheridan,J.P., Marsters,S.A., Pitti,R.M., Gurney,A., Skubatch,M., Baldwin,D., Ramakrishnan,L., Gray,C.L., Baker,K., Wood,W.I., Goddard,A.D., Godowski,P., and Ashkenazi,A. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-821. 67. Skehan,P., Storeng,R., Scudiero,D., Monks,A., McMahon,J., Vistica,D., Warren,J.T., Bokesch,H., Kenney,S., and Boyd,M.R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl.Cancer Inst., 82, 1107-1112. 67. Sufan,R.I., Jewett,M.A., and Ohh,M. (2004) The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am.J Physiol Renal Physiol, 287, F1-F6. 68. Tanaka,Y., Yoshihara,K., Tsuyuki,M., and Kamiya,T. (1994) Apoptosis induced by adenosine in human leukemia HL-60 cells. Exp.Cell Res., 213, 242-252. 69. Tartaglia,L.A., Ayres,T.M., Wong,G.H., and Goeddel,D.V. (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell, 74, 845-853. 70. Thornberry,N.A. and Lazebnik,Y. (1998) Caspases: enemies within. Science, 281, 1312-1316. 71. Thornberry,N.A., Rano,T.A., Peterson,E.P., Rasper,D.M., Timkey,T., Garcia-Calvo,M., Houtzager,V.M., Nordstrom,P.A., Roy,S., Vaillancourt,J.P., Chapman,K.T., and Nicholson,D.W. (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol.Chem., 272, 17907-17911. 72. Tsujimoto,Y. and Shimizu,S. (2002) The voltage-dependent anion channel: an essential player in apoptosis. Biochimie, 84, 187-193. 73. Tulis,D.A., Bohl Masters,K.S., Lipke,E.A., Schiesser,R.L., Evans,A.J., Peyton,K.J., Durante,W., West,J.L., and Schafer,A.I. (2002) YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem.Biophys.Res.Commun., 291, 1014-1021. 74. Tulis,D.A., Durante,W., Peyton,K.J., Chapman,G.B., Evans,A.J., and Schafer,A.I. (2000) YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem.Biophys.Res.Commun., 279, 646-652. 75. Vander Heiden,M.G., Chandel,N.S., Li,X.X., Schumacker,P.T., Colombini,M., and Thompson,C.B. (2000) Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival. Proceedings of the National Academy of Sciences, 97, 4666-4671. 76. Walczak,H., gli-Esposti,M.A., Johnson,R.S., Smolak,P.J., Waugh,J.Y., Boiani,N., Timour,M.S., Gerhart,M.J., Schooley,K.A., Smith,C.A., Goodwin,R.G., and Rauch,C.T. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J, 16, 5386-5397. 77. Wallach,D., Varfolomeev,E.E., Malinin,N.L., Goltsev,Y.V., Kovalenko,A.V., and Boldin,M.P. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu.Rev.Immunol., 17, 331-367. 78. Wang,J.P., Chang,L.C., Raung,S.L., Hsu,M.F., Huang,L.J., and Kuo,S.C. (2002) Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms. Biochem.Pharmacol, 63, 577-585. 79. Wang,S.W., Pan,S.L., Guh,J.H., Chen,H.L., Huang,D.M., Chang,Y.L., Kuo,S.C., Lee,F.Y., and Teng,C.M. (2005) YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] Exhibits a Novel Antiproliferative Effect and Arrests the Cell Cycle in G0-G1 in Human Hepatocellular Carcinoma Cells. Journal of Pharmacology And Experimental Therapeutics, 312, 917-925. 80. Wyllie,A.H. (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature, 284, 555-556. 81. Yagita,H., Takeda,K., Hayakawa,Y., Smyth,M.J., and Okumura,K. (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci., 95, 777-783. 82. Ye,H., Cande,C., Stephanou,N.C., Jiang,S., Gurbuxani,S., Larochette,N., Daugas,E., Garrido,C., Kroemer,G., and Wu,H. (2002) DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat.Struct.Biol., 9, 680-684. 83. Yeo,E.J., Chun,Y.S., Cho,Y.S., Kim,J., Lee,J.C., Kim,M.S., and Park,J.W. (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl.Cancer Inst., 95, 516-525. 84. Zhang,X.D., Franco,A.V., Nguyen,T., Gray,C.P., and Hersey,P. (2000) Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol., 164, 3961-3970. 85. Zheng,T.S., Schlosser,S.F., Dao,T., Hingorani,R., Crispe,I.N., Boyer,J.L., and Flavell,R.A. (1998) Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc.Natl.Acad.Sci.U.S A, 95, 13618-13623. 86. Zong,W.X., Lindsten,T., Ross,A.J., MacGregor,G.R., and Thompson,C.B. (2001) BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes and Development, 15, 1481-1486. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24267 | - |
dc.description.abstract | 目前,腎癌病人之致死率相當高,但是有效治療的藥物非常少。本篇論文主要利用 YC-1 對腎癌細胞 A498 具有相當高敏感度的特性,進一步了解 YC-1 誘發腫瘤細胞凋亡之機轉,和在動物活體之藥效。實驗結果發現,使用MTT及SRB檢測法,YC-1對於 A498細胞之IC50約在10-7 ~ 10-8 M左右,且具有濃度依賴性的關係。而利用DAPI做螢光染色的結果,證實YC-1可以引起 A498細胞 chromatin condensation 的現象。進一步以流式細胞儀來觀測細胞週期變化,發現 YC-1 引起 A498 細胞在sub-G1期數目的增加具有時間依賴性的關係。在Bcl-2家族蛋白及caspases方面之探討, anti-apoptotic 之 Bcl-xL、Bcl-2 蛋白的表現有減少,而pro-apoptotic 之 Bax 蛋白的表現並無明顯的變化;另外也發現 Bid 受 YC-1 的刺激而被裂解。而caspase-3與caspase-8都有被活化的現象,然而對 caspase-9 卻沒有影響。同樣的caspase-3的受質,PARP,也有觀察到同步被caspase-3活化的結果。而使用caspases抑制劑,z-VAD-fmk則可以有效的逆轉YC-1對 A498細胞所造成的細胞凋亡作用。利用調控細胞凋亡的 protein kinases 之抑制劑進一步探討 YC-1 所支配的訊息傳遞。結果發現只有 SP600125 (a JNK inhibitor) 可顯著地逆轉由 YC-1 所誘發之細胞凋亡,而 SB203580 (a p38 inhibitor) 並無作用。以西方點墨法進一步觀察到 YC-1 在3小時的時間點就能使JNK 磷酸化,並證實SP600125的確能有效的抑制YC-1所造成的細胞凋亡作用,表示JNK為YC-1造成細胞凋亡作用之重要調控途徑。由於YC-1可以促成caspase-8的活化,接著探討死亡受體及其ligands的表現。結果顯示 YC-1 可促使 FasL 蛋白質增加,對於 death receptors (Fas,DR4 和 DR5) 及TRAIL並無顯著的影響。另外透過螢光顯微照相的結果,發現 YC-1 亦可在短時間內造成 Fas clustering的現象。在裸鼠動物實驗中更進一步證實 YC-1 於體內具有抗癌的活性。總而言之,在藥理機轉研究上,YC-1 乃藉由活化 JNK 進而增加 DILs (death-inducing ligands),另一方面促使 Fas clustering 現象,進一步驅動 caspase-8 和 caspase-3 的活化造成細胞凋亡;並且發現在動物體內具有抗腫瘤生長的作用。因此,YC-1 為一個具有潛力發展成為良好的抗癌候選藥物。 | zh_TW |
dc.description.abstract | The survival rate of patients affected with renal cancer carcinoma was very low and effective drugs were very few. In this study, we used the character of high sensitivity for YC-1 in A498 cells and tried to understand the mechanism of YC-1-inducing tumor cell apoptosis and the potency in vivo studies. We found that the 50% inhibition of cell survival or cell growth(IC50)of YC-1 in A498 cells was 10-7 ~ 10-8 M as measured by MTT and SRB assay. The YC-1-induced chromatin condensation was identified by DAPI staining technique in A498 cells. By using flow cytometry to detect the progression of cell cycle, we found that the population in subG1 phase dramatically increased in response to YC-1 in a concentration-dependent manner. By using Western blotting analysis to investigate the expressions of Bcl-2 family of proteins and caspase cascades, the data showed that the anti-apoptotic protein, Bcl-xL and Bcl-2, but not other proteins was down-regulated in response to YC-1 treatment. Furthermore, Bid was cleaved in response to YC-1 stimulus. The data also demonstrated that YC-1 significantly induced the cleavage of caspase-3 and caspase-8 but had little influence on caspase-9. The substrate of caspase-3, PARP, in the same way, was cleaved by caspase-3. Additionally, the caspase inhibitor, z-VAD-fmk, could effectively reverse YC-1-induced apoptosis in A498 cells. Then, we used the protein kinase inhibitors, and the regulators in apoptosis pathway to understand which pathway maybe involved. The data showed that SP600125 (a JNK inhibitor) but not SB203580 (a p38 inhibitor) could significantly reverse YC-1-induced apoptosis in A498 cells. By using Western blotting analysis, our data demonstrated the phosphorylation of JNK after YC-1 treatment. Besides, we also confirmed that SP600125 could effectively inhibit apoptosis induced by YC-1. These data demonstrated that JNK is an important factor in YC-1-induced apoptosis in A498 cells. Since caspase-8 was activated, we therefore examine the expressions of death receptors and their ligands. The data revealed that YC-1 induced FasL and up-regulation but had no significant influence on expressions of death receptors(Fas, DR4 and DR5)and TRAIL. Our data also confirmed that YC-1 induced Fas receptor clustering within a short time. Furthermore, YC-1 showed an in vivo anticancer efficacy in xenograft models. It is suggested that YC-1 induces JNK phosphorylation and then up-regulation of DILs(death-inducing ligands). On the other hand, YC-1 also induces Fas receptor clustering and then promotes the activation of caspase-8 and caspase-3, resulting in apoptosis. Our data also demonstrate the anti-tumor effect of YC-1 in vivo study. These data reveal that YC-1 is an excellent candidate for the development of anticancer drug. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:20:12Z (GMT). No. of bitstreams: 1 ntu-94-R92443007-1.pdf: 2283819 bytes, checksum: 5796c67f945eb05e575ce767c4b573f9 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 縮寫表......................2
中文摘要.....................4 英文摘要.....................6 文獻回顧.....................8 前言...................8 亮細胞癌.................10 細胞凋亡.................10 YC-1...................17 實驗材料與方法..................26 結果.......................38 討論.......................46 結論.......................54 圖表.......................55 參考文獻.....................68 | |
dc.language.iso | zh-TW | |
dc.title | YC-1經由活化JNK途徑而誘發腎癌細胞 A498凋亡之機轉探討 | zh_TW |
dc.title | YC-1 induces apoptosis of human renal carcinoma A498 cells through activating JNK pathway | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 顧記華,楊春茂,黃德富,顏茂雄 | |
dc.subject.keyword | YC-1,腎癌,JNK,A498,細胞凋亡, | zh_TW |
dc.subject.keyword | YC-1,human renal carcinoma,JNK,A498,apoptosis, | en |
dc.relation.page | 77 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2005-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 2.23 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。